2025
Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer
Tan J, Yang S, Dinan M, Chiang A, Gross C, Wang S. Biomarker-Specific Survival and Medication Cost for Patients With Non–Small Cell Lung Cancer. JAMA Network Open 2025, 8: e2514519. PMID: 40493365, PMCID: PMC12152704, DOI: 10.1001/jamanetworkopen.2025.14519.Peer-Reviewed Original ResearchConceptsAdvanced non-small cell lung cancerNon-small cell lung cancerEGFR variationPD-L1ALK rearrangementCell lung cancerDriver alterationsMedical costsLung cancerCohort studyProgrammed cell death 1 ligand 1Cell death 1 ligand 1Biomarker statusMedian overall survivalRetrospective cohort studyLower medical costsOverall survivalTargeted therapyNon-smallPatient cohortMonthly medical costsFollow-upStudy cohortBiomarker testingAssociated with higher costsValidation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG.
Othus M, Kurzrock R, Patel S, Chae Y, Patel S, Sosman J, Snyder Charen A, Rizvi N, LaVallee T, Felquate D, Burton E, Futreal P, Sullivan R, Kluger H, Tawbi H. Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG. Journal Of Clinical Oncology 2025, 43: 2656-2656. DOI: 10.1200/jco.2025.43.16_suppl.2656.Peer-Reviewed Original ResearchOverall survivalMartingale residual plotsAdjuvant settingPD-(L)1Shorter OSNo significant differencePrimary resistanceAssociated with significantly shorter OSHazard ratioHigh-risk resected stagePD-(L)1 inhibitorsImmunotherapy of cancerSignificant differenceConfidence intervalsCox regression modelsClinical trial interpretationAdjuvant cohortAdjuvant pembrolizumabImmunotherapy resistanceLate recurrenceResected stageEarly recurrenceSWOG trialsIO agentsPatient cohortClinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts.
Witowski J, Choucair K, Elayoubi J, Chiru E, Chan N, Kang Y, Howard F, Ostrovnaya I, Schnabel F, Abdulsattar W, Zong Y, Daoud L, Vetter M, Pan J, Laurinavičius A, Piening B, Bifulco C, Brufsky A, Esteva F, Pusztai L. Clinical validation of a multi-modal Ataraxis AI platform for recurrence prediction in early-stage breast cancer across multiple patient cohorts. Journal Of Clinical Oncology 2025, 43: 549-549. DOI: 10.1200/jco.2025.43.16_suppl.549.Peer-Reviewed Original ResearchDisease-free intervalOncotype DXBreast cancer recurrenceClinical characteristicsBreast cancerC-indexHazard ratioCancer recurrenceStage I–III BC patientsEarly-stage breast cancerMultiple patient cohortsHarrell's C-indexDuctal histologyER/PR/HER2 statusHER2+BC subtypesBC patientsPatient cohortValidation cohortTNM stagePrediction of breast cancer recurrenceClinical variablesExternal cohortH&E slidesMultivariate analysisRobotic-Assisted Percutaneous Coronary Intervention: Final Results of the PRECISION and PRECISION GRX Studies
Mahmud E, Madder R, Wohns D, Schussler J, Salisbury A, Campbell P, Patel T, Lombardi W, Nicholson W, Parikh M, Kelm N, Waksman R, Lansky A, Weisz G. Robotic-Assisted Percutaneous Coronary Intervention: Final Results of the PRECISION and PRECISION GRX Studies. Journal Of The Society For Cardiovascular Angiography & Interventions 2025, 103655. DOI: 10.1016/j.jscai.2025.103655.Peer-Reviewed Original ResearchTechnical success rateR-PCIPercutaneous coronary interventionTechnical successClinical successSuccess rateCoronary interventionCalcific lesionsLack of clinical dataSymptomatic coronary artery diseaseClinical success rateSingle-arm studyAdverse cardiovascular eventsCoronary artery diseaseBifurcation lesionsManual PCIMulticenter experienceComplex lesion typePatient cohortCardiovascular eventsResidual stenosisClinical dataRobotic percutaneous coronary interventionArtery diseaseLesionsNatriuretic response prediction equation for use with oral diuretics in heart failure
Ivey-Miranda J, Rao V, Cox Z, Moreno-Villagomez J, Mastache D, Collins S, Testani J. Natriuretic response prediction equation for use with oral diuretics in heart failure. European Heart Journal 2025, 46: 2410-2418. PMID: 40272149, PMCID: PMC12208776, DOI: 10.1093/eurheartj/ehaf268.Peer-Reviewed Original ResearchConceptsMechanisms of diuretic resistanceArea under the curvePoor diuretic responseDiuretic responseHeart failureDiuretic doseOral diureticsNatriuretic responseHF patient cohortsLoop diuretic doseOral loop diureticsUrine samplesTimed urine collectionsOral loopDiuretic resistanceLoop diureticsDiuretic administrationUrine volumePatient cohortUrine collectionStudy visitsDiureticsPatientsUrineDose837 Impact of Autologous, Non-Autologous, Synthetic Tissue Substitutes in Burns 2016-2021: Analysis of National Burn Repository
Crombie R, Witherel C. 837 Impact of Autologous, Non-Autologous, Synthetic Tissue Substitutes in Burns 2016-2021: Analysis of National Burn Repository. Journal Of Burn Care & Research 2025, 46: s282-s282. PMCID: PMC11958335, DOI: 10.1093/jbcr/iraf019.368.Peer-Reviewed Original ResearchNon-autologousLong-term safetyHealth economic implicationsBurn careClinical benefitPatient cohortTissue substituteClinical studiesBurn patientsICD-10 codesNational Burn RepositoryPatientsThermal injuryCare algorithmInvestigated groupsBurn RepositoryICD-10Procedure codesTissueImpact of cAMPSkin substitutesVolumetric Abdominal Aortic Aneurysm Analysis in Post EVAR Surveillance Settings
Simmons K, Weiss D, Aboian M, Lin M, Bousabarah K, Renninghoff D, Holler W, Deuschl C, Fischer U, Aboian E. Volumetric Abdominal Aortic Aneurysm Analysis in Post EVAR Surveillance Settings. Annals Of Vascular Surgery 2025, 114: 241-250. PMID: 40049548, DOI: 10.1016/j.avsg.2025.02.009.Peer-Reviewed Original ResearchAbdominal aortic aneurysmEndovascular aortic repairEarly detection of abdominal aortic aneurysmsDetection of abdominal aortic aneurysmsLong-term follow-up dataAneurysm-related mortalityVolumetric analysisAneurysm sac enlargementAssociated with older ageSubgroup of patientsFollow-up dataHigh-risk aneurysmsMaximum diameter measurementsAortic repairSac enlargementAAA enlargementCT angiogramMetformin therapyPatient cohortAortic aneurysmClinical factorsUnivariate analysisClinical variablesAneurysm volumeMedical recordsCACNA1G, A Heterotaxy Candidate Gene, Plays a Role in Ciliogenesis and Left‐Right Patterning in Xenopus tropicalis
Kostiuk V, Kabir R, Akbari R, Rushing A, González D, Kim A, Kim A, Zenisek D, Khokha M. CACNA1G, A Heterotaxy Candidate Gene, Plays a Role in Ciliogenesis and Left‐Right Patterning in Xenopus tropicalis. Genesis 2025, 63: e70009. PMID: 40008628, PMCID: PMC11867209, DOI: 10.1002/dvg.70009.Peer-Reviewed Original ResearchConceptsCongenital heart diseaseCACNA1GLow-voltage-activated calcium channelsExpression of Cacna1gCalcium channelsPatient cohortCardiac functionLR patterningHeterotaxyLR organizerChannel familyCACNA1SHeart diseaseLeft-rightG expressionXenopus tropicalisAbnormal expressionProcess of cilia formationCardiac loopingMultiple organsSignaling cascadesLR asymmetryPatientsT-typeEmbryonic developmentThe Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients
Antonios J, Adenu-Mensah N, Theriault B, Millares-Chavez M, Huttner A, Aboian M, Chiang V. The Central Vein Sign as a Radiologic Tool to Predict the Diagnosis of Radiation Necrosis in Intracranial Metastatic Cancer Patients. Clinical And Translational Neuroscience 2025, 9: 10. DOI: 10.3390/ctn9010010.Peer-Reviewed Original ResearchCentral vein signRadiation necrosisTumor progressionDiagnosis of radiation necrosisDifferentiate RNCerebral radiation necrosisIntracranial metastatic diseaseCancer therapy responseMetastatic cancer patientsNon-invasive markerMetastatic diseaseSurgical biopsyTherapy responsePredictive markerPatient cohortPrimary treatmentRadiological toolsCancer patientsRadiological imagingTreatment decisionsPerivascular spacesPatientsTreatmentNecrosisMarkersReal-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform
Exarchos A, Bourla A, Kaur M, Schulze K, Maund S, Cao Y, Zhao Y, Williams E, Gaffey S, Zuniga R, Lakhanpal S, Antic V, Doral M, Sy J, Meropol N, Chiang A. Real-world enrollment for a prospective clinico-genomic database using a pragmatic technology-enabled platform. Contemporary Clinical Trials Communications 2025, 44: 101446. PMID: 40027276, PMCID: PMC11869879, DOI: 10.1016/j.conctc.2025.101446.Peer-Reviewed Original ResearchCirculating tumor DNAClinico-genomic datasetsRecurrent metastatic non-small cell lung cancerExtensive-stage small-cell lung cancerLung cancerMetastatic non-small cell lung cancerStandard line of therapyCirculating tumor DNA testingSmall-cell lung cancerNon-small cell lung cancerLines of therapyCell lung cancerClinico-genomic databaseSerial blood samplesPre-specified timepointsCommunity-based research sitesTumor DNAPatient cohortClinical dataStage IVGenomic profilingPrognostic biomarkerAcademic centersUS sitesBlood samples
2024
Variables Affecting 90-Day Overall Reimbursement After Anterior Cruciate Ligament Reconstruction: Analysis of Nearly 250,000 Patients in the United States
Halperin S, Prenner S, Dhodapkar M, Santos E, Medvecky M, Grauer J. Variables Affecting 90-Day Overall Reimbursement After Anterior Cruciate Ligament Reconstruction: Analysis of Nearly 250,000 Patients in the United States. Orthopaedic Journal Of Sports Medicine 2024, 12: 23259671241300500. PMID: 39697605, PMCID: PMC11653448, DOI: 10.1177/23259671241300500.Peer-Reviewed Original ResearchAnterior cruciate ligament reconstructionElixhauser Comorbidity IndexCruciate ligament reconstructionAdverse eventsPatient ageLigament reconstructionHealth care systemAssociated with older agePostoperative adverse eventsMultivariate logistic regressionInsurance typeFactors associated with variabilityOverall reimbursementCare systemPatient cohortSurgery statusOutpatient basisFemale sexMultivariate linear regressionComorbidity indexComorbidity burdenEmergency department visitsPatientsInpatient proceduresOrthopaedic proceduresFuture directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology
Della Porta M, Bewersdorf J, Wang Y, Hasserjian R. Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology. Histopathology 2024, 86: 158-170. PMID: 39450427, DOI: 10.1111/his.15353.Peer-Reviewed Original ResearchAcute myeloid leukemiaIntegration of genomic dataGenomic informationGenomic dataPresence of SF3B1 mutationsDisease entityMethylation profilesAML classificationRecurrent genetic abnormalitiesHaematopoietic cell proliferationPercentage of myeloblastsGene expressionGenetic featuresMultiple diagnostic modalitiesPatient risk stratificationSF3B1 mutationsBlast countDisease pathogenesisGenetic abnormalitiesCell proliferationTP53 abnormalitiesDiagnostic modalitiesMyeloid leukemiaBone marrowPatient cohortRate and Timing of Revision and Contralateral Anterior Cruciate Ligament Reconstruction Relative to Index Surgery
Halperin S, Dhodapkar M, McLaughlin W, Hewett T, Grauer J, Medvecky M. Rate and Timing of Revision and Contralateral Anterior Cruciate Ligament Reconstruction Relative to Index Surgery. Orthopaedic Journal Of Sports Medicine 2024, 12: 23259671241274671. PMID: 39376746, PMCID: PMC11457252, DOI: 10.1177/23259671241274671.Peer-Reviewed Original ResearchAnterior cruciate ligament (ACL) reconstructionContralateral reconstructionRevision ACLRContralateral ACL injuryACL injuryMultivariate logistic regressionLevel of evidenceIpsilateral revisionsCross-sectional studyPatient cohortIpsilateral reconstructionFemale sexMultivariate analysisPatient counselingInjury-prevention programsPatientsTime of revisionYounger ageGraft reinjuryAdministrative databasesLogistic regressionStudy periodACLInjuryPearlDiverApplying Language Models to Radiology Text for Identifying Oligometastatic Non-Small Cell Lung Cancer
Moore N, Laird J, Verma N, Hager T, Sritharan D, Lee V, Maresca R, Chadha S, Park H, Aneja S. Applying Language Models to Radiology Text for Identifying Oligometastatic Non-Small Cell Lung Cancer. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e644. DOI: 10.1016/j.ijrobp.2024.07.1417.Peer-Reviewed Original ResearchNon-small cell lung cancerOligometastatic diseaseCell lung cancerRadiologic impressionTumor RegistryTest cohortOligometastatic non-small cell lung cancerIV non-small cell lung cancerStage IV non-small cell lung cancerLung cancerConvolutional neural networkMetastasis-directed therapyOligometastatic NSCLC patientsMonths of diagnosisLanguage modelClinician reviewNSCLC patientsPatient cohortClinical dataScreening patientsSubgroup analysisBrain MRIClinical textBurden of diseaseClinical relevancePhenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies
Gu S, Butt A, Schulz V, Rinder H, Lee A, Gallagher P, Hwa J, Bona R. Phenotypic and genotypic evaluation of bleeding diagnostic dilemmas: Two case studies. Blood Cells Molecules And Diseases 2024, 110: 102893. PMID: 39260211, DOI: 10.1016/j.bcmd.2024.102893.Peer-Reviewed Original ResearchInherited platelet disordersClinically significant bleedingCases of patientsHeterogeneous group of conditionsGroup of conditionsSignificant bleedingDiagnostic yieldDiagnostic dilemmaPlatelet disordersBleeding disordersEvaluating patientsPatient cohortMolecular pathogenesisMass cytometryHeterogeneous groupPatientsMultimodal approachBleedingImprove patient careDiagnosisDisordersPatient careGenetic sequencesLaboratory testing approachPotential utilityMDS-772 Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/Neoplasms
Zeidan A, Olopoenia A, Costantino H, Modi K, Salimi T, Washington T, Krenitsky J, Epstein R. MDS-772 Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/Neoplasms. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s406. DOI: 10.1016/s2152-2650(24)01382-x.Peer-Reviewed Original ResearchHMA therapyRetrospective analysis of adult patientsAnalysis of adult patientsRoute of administrationMedian life expectancyPropensity score matchingHypomethylating agentsMDS treatmentBurden of treatmentAdult patientsPatient cohortInfusion dayParenteral treatmentMatched cohortResults PatientsRetrospective analysisOlder patientsEmergency room visitsCancer therapyHMA treatmentParenteral administrationTherapyPatientsOutpatient settingScore matchingPotential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
McQuaid C, Ryckman T, Menzies N, White R, Cohen T, Kendall E. Potential of Pan-Tuberculosis Treatment to Drive Emergence of Novel Resistance - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1571-1579. PMID: 39043388, PMCID: PMC11286077, DOI: 10.3201/eid3008.240541.Peer-Reviewed Original ResearchConceptsResistance to novel drugsStandard of careAntimicrobial resistanceIncreasing prevalence of antimicrobial resistancePrevalence of antimicrobial resistanceIncreased prevalenceDrug susceptibility testingCompare treatment outcomesFirst-line drugsNovel drugsTB patient cohortTreatment regimensPatient cohortNew tuberculosisRegimensTreatment outcomesComponent drugsDrugCohortTuberculosisCDCUniversal useClinicCarePrevalenceTRIM71 mutations cause a neurodevelopmental syndrome featuring ventriculomegaly and hydrocephalus
Duy P, Jux B, Zhao S, Mekbib K, Dennis E, Dong W, Nelson-Williams C, Mehta N, Shohfi J, Juusola J, Allington G, Smith H, Marlin S, Belhous K, Monteleone B, Schaefer G, Pisarska M, Vásquez J, Estrada-Veras J, Keren B, Mignot C, Flore L, Palafoll I, Alper S, Lifton R, Haider S, Moreno-De-Luca A, Jin S, Kolanus W, Kahle K. TRIM71 mutations cause a neurodevelopmental syndrome featuring ventriculomegaly and hydrocephalus. Brain 2024, 147: 4292-4305. PMID: 38833623, PMCID: PMC11629693, DOI: 10.1093/brain/awae175.Peer-Reviewed Original ResearchCongenital hydrocephalusCerebral ventriculomegalyStructural brain defectsCohort of patientsAnalysis of human embryosNeurodevelopmental syndromeCorpus callosum dysgenesisWhite matter hypoplasiaSingle-cell transcriptome analysisNeural stem cellsDysmorphic featuresTransmitted variantsPatient cohortVentriculomegalyNHL domainCross-sectional analysisLin-41Subcellular localizationBrain defectsDevelopmental delayHuman embryosProcessing bodiesHomologous positionsPatientsStem cellsTime toxicity for patients receiving oral versus parenteral hypomethylating agents for myelodysplastic syndromes/neoplasms (MDS).
Epstein R, Zeidan A, Olopoenia A, Costantino H, Modi K, Salimi T, Washington T, Krenitsky J. Time toxicity for patients receiving oral versus parenteral hypomethylating agents for myelodysplastic syndromes/neoplasms (MDS). Journal Of Clinical Oncology 2024, 42: 6568-6568. DOI: 10.1200/jco.2024.42.16_suppl.6568.Peer-Reviewed Original ResearchHMA therapyHypomethylating agentsRetrospective analysis of adult patientsAnalysis of adult patientsEmergency roomRoute of administrationTime burdenMedian life expectancyPropensity score matchingMDS treatmentBurden of treatmentAdult patientsParenteral treatmentPatient cohortInfusion dayRetrospective analysisCancer therapyPatientsTherapyOutpatient settingScore matchingTreatment groupsCohortHealthcare daysOutpatient visitsHematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria
Tan W, Ahmad A, Zhou Y, Nathan A, Ogunbo A, Gbolahan O, Kallam N, Smith R, Khalifeh M, Tan W, Cohen D, Volanis D, Walter F, Sasieni P, Kamat A, Kelly J. Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria. European Urology Oncology 2024, 8: 87-93. PMID: 38811250, DOI: 10.1016/j.euo.2024.05.005.Peer-Reviewed Original ResearchCancer risk scoreRenal bladder ultrasoundTa bladder cancerUrinary tract cancerRisk scoreValidation cohortBladder cancerHealth care cost savingsBladder ultrasoundDiagnosis of urinary tract cancerInvasive proceduresDevelopment cohortIdentification of cancerSuspicion of bladder cancerSecondary careIndependent validation cohortReceiver operating characteristic curveUK hospitalsArea under the receiver operating characteristic curveOutcome measuresTriage of patientsConsecutive patientsPatient cohortCystoscopyHematuria
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply